**Aetiology and outcome of non-traumatic coma in African children: protocol for a systematic review and meta-analysis**

**PROSPERO Registration:** CRD42020141937

**Authors**

Dr Stephen Ray1,2,3, Dr Charlotte Fuller2,3,4, Ms Alexandra Boubour3,5, Dr Laura Bonnett6, Dr Karl Seydel\*2,3,7, Dr Michael Griffiths\*1,8,9

\*authors contributed equally

1 Institute of Infection and Global Health, University of Liverpool, Liverpool UK

2 Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi

3 Blantyre Malaria Project, Blantyre, Malawi

4 Leeds Children’s Hospital, Leeds Teaching Hospitals Trust, UK

5 Columbia University Irving Medical Center, New York, USA

6 Department of Biostatistics, University of Liverpool, Liverpool UK

7 Michigan State University, East Lansing, USA

8 Department of Neurology, Alder Hey Children's NHS Trust, UK

9 National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, UK

**Contacts**

Dr Stephen Ray | sray@liverpool.ac.uk

Dr Charlotte Fuller | [cfuller@doctors.org.uk](mailto:cfuller@doctors.org.uk)

Ms Alexandra Boubour | [alb2275@cumc.columbia.edu](mailto:alb2275@cumc.columbia.edu)

Dr Laura Bonnett | [L.J.Bonnett@liverpool.ac.uk](mailto:L.J.Bonnett@liverpool.ac.uk)

Dr Karl Seydel | [seydel@msu.edu](mailto:seydel@msu.edu)

Dr Michael Griffiths | [m.j.griffiths@liverpool.ac.uk](mailto:m.j.griffiths@liverpool.ac.uk)

**Guarantor**

Dr Stephen Ray

**Corresponding Author**

Stephen Ray

Malawi-Liverpool Wellcome Trust Clinical Research Programme

P.O. Box 30096

Chichiri, Blantyre 3

Malawi

[dr.stj.ray@gmail.com](mailto:dr.stj.ray@gmail.com)

+265 991801840

**ABSTRACT**

**Background:** Non-traumatic coma is a common acute childhood presentation to healthcare facilities in Africa and is associated with high morbidity and mortality. Historically, the majority of cases were attributed to cerebral malaria (CM), but with the recent drastic reduction in malaria incidence, non-malarial coma is a larger proportion of cases, and determining the aetiology is diagnostically challenging, particularly in resource-limited settings. The purpose of this paper is to provide a protocol for a systematic review on the aetiology and clinical outcome of non-traumatic coma in African children.

**Methods:** The following databases will be searched: MEDLINE, Embase, and Scopus. Published articles of all languages and publication date on non-traumatic coma in African children will be included. Disease-specific articles will also be included, providing that coma is associated. Two authors will independently assess the studies for risk of bias, following which the data will be analysed, synthesised, and discussed.

**Discussion:** This systematic review will provide a summary of the best available evidence on the aetiology and outcome of non-traumatic coma in African children. This review is registered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020141937).

**Keywords:** Coma, non-traumatic, aetiology, children, Africa,

**BACKGROUND**

Non-traumatic coma is a common acute childhood presentation to healthcare facilities throughout Africa. Infectious causes of deep coma (defined as Blantyre Coma Scale (BCS) ≤2) include cerebral malaria (CM), acute bacterial meningitis (ABM), viral encephalitides, and HIV-associated opportunistic pathogens, such as Tuberculosis and Cryptococcal disease, and non-infectious causes include metabolic abnormalities and toxins (1-3). In malaria-endemic regions, CM is diagnosed in children with coma and peripheral malarial parasitaemia with no other identifiable cause (1). Limited diagnostic resources in many African settings and the phenomenon of asymptomatic malarial parasitaemia have both rendered the alternate diagnoses of childhood coma under-described, resulting in a poor epidemiological understanding of this clinical presentation (4,5). A study in Kenya revealed that less than half of children admitted with acute non-traumatic coma had an identified cause (6). With the recent drastic reduction in malaria incidence, it is postulated that non-malarial coma represents a larger proportion of coma cases (6). Non-traumatic coma in children is associated with high mortality (15-58%) and significant neurological sequelae (31-68%) (7-9). The long-term effects of coma on cognition and educational achievement is less commonly described, and existing literature primarily focuses on CM (10,11). Yet, these effects play an important role in the social and economic development of low-resource countries (12).

There is a paucity of data in the aetiology of non-malarial coma in Africa (3). Given the high burden of morbidity and mortality associated with this clinical presentation, an overview of the literature to date is vital to direct further research. Gwer *et al.* (2013) performed a review of fourteen studies on childhood non-traumatic coma in both Africa and Asia (9). However, there have subsequently been multiple larger studies that have used molecular diagnostics and other adjuvant diagnostic capacities, such as magnetic resonance imaging (MRI) and electroencephalogram (EEG). Non-traumatic coma outcomes in Africa are heterogenous between studies and long term follow up is sparse. A systematic review on outcome of non-traumatic coma has not yet been investigated (9).

Using the Population, Intervention, Comparator, Outcome and Study Designs (PICOS) framework, we will aim to examine the best available evidence on the aetiology of acute non-traumatic coma in African children (13). In this systematic review, we will also quantify the associated morbidity and mortality of disease-specific non-malarial coma in this setting. Lastly, we will suggest direction for future research in this important yet under-researched area.

**METHODS/DESIGN**

**Outcomes of Interest**

The primary outcome of this study is to determine the aetiology of non-traumatic coma in African children. The secondary outcome is to determine the overall morbidity (particularly neurological and cognitive-behavioural sequelae) and mortality of disease-specific states with non-traumatic coma in African children. These outcomes will provide critical data needed to inform future directions for research.

**Protocol Development and Registration**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) was used to develop this protocol (14) (Table 1), and we will use elements of the Cochrane Handbook of Systematic Reviews to guide the systematic review (15). The Population, Intervention, Comparator, Outcome and Study Designs (PICOS) framework was used to develop the inclusion and exclusion criteria (13). This review is registered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020141937).

**Eligibility Criteria**

Studies of all design methods, including cohort studies and randomised-controlled trials, that are either prospective or retrospective will be included. Studies from any country in Africa will be considered, including those from multi-centre trials with data for children from African countries which can be uniquely identified. Publication dates and language will not be restricted. However, case reports, case series, commentaries and editorials will be excluded from the review. We will exclude all publications which do not contain primary data.

Studies with a primary focus of acute non-traumatic coma in children (1 month-16 years old), particularly those diagnosed with febrile encephalopathy or suspected central nervous system infection (as defined by BCS≤2, or equivalent as per a coma assessment tool) will be included. Disease-specific studies will also be included providing coma is associated and reported.

**Electronic Search Strategy**

We will search the following databases: (1) MEDLINE, (2) Embase, and (3) Scopus from inception. The complete search strategy for MEDLINE is included in Table 2. We will search conference proceedings and databases of ongoing studies to identify studies not found in the databases listed above. Reference lists of eligible studies and relevant systematic reviews will be searched to identify additional studies to be considered for inclusion. All records identified from the search will be imported to EndNote X9.3.1 (Clarivate Analytics, Philadelphia, PA), a citation management programme, following which duplicates will be removed.

**Screening and Selection Criteria**

Two authors (SR and CF) will independently screen the title and abstract of each publication. Those articles obviously irrelevant to the review, or which do not clearly meet the inclusion criteria will be excluded. The number of records screened and excluded will be recorded. The full text of the identified studies will then be individually assessed for eligibility against the pre-determined criteria, by three reviewers (CF, SR, and AB). Discrepancies will be resolved by internal discussion and consultation with an additional author (MG) if required. The reasons for exclusion of full-text articles will be documented.

**Data Extraction**

We will use the Cochrane Effective Practice and Organisation of Care (EPOC) standard data collection form and adapt it for study characteristics and outcome data (17). Two review authors will pilot the form on a randomly selected subset of 10% of included studies.

The following information will be extracted from each included trial:

1. Author and Publication Details: Name of first author, corresponding author, publication year and journal, PubMed and registration ID, and funding source.
2. Study Characteristics: Study design, duration, location(s), setting, timing of data collection (prospective or retrospective), methods of recruitment, duration of follow-up and statistical methods, completeness of outcome data, and Cochrane variables of bias (16).
3. Participants: Number, age range, mean age, gender, definition of coma, inclusion and exclusion criteria, withdrawals and exclusions, method of diagnosis (microbiological methods used, including culture and polymerase chain reaction (PCR) methods), co-morbidities, and other relevant characteristics, such as human immunodeficiency virus (HIV) and nutritional status.
4. Outcome: Clinical diagnosis, microbiological diagnosis, clinical outcome, such as fatality or neurological and/or neurocognitive sequelae for each clinical syndrome, and microbiological diagnosis. Neurological sequelae stratified into subtypes including motor, vision, hearing, epilepsy, and cognitive-behavioural.

Attempts to contact authors will be made for missing outcome data or of key study characteristics.

**Assessment of Risk of Bias**

Three reviewers (CF, SR, and AB) will independently conduct a bias risk assessment at the study level in order to assess the quality of the included studies. The validated Cochrane Collaboration Risk of Bias tool (16) will be used as a framework upon which to guide quality assessments for randomised controlled trials. The Newcastle-Ottawa Scale (NOS) will be used for case-control and cohort studies. Critical Appraisal Skills Programme (CASP) checklists will be used for other study types (18,19).

Risk of bias for each domain will be recorded as high, low, or unclear. Any disagreements will be discussed with a third reviewer (MG).

**Data Synthesis**

Because of concerns about meta-analysis of proportions on very heterogeneous populations, we plan a meta-analysis of outcome stratified by inclusion criteria where possible. A narrative synthesis of the data will also be provided including summary and explanation of characteristics and findings of included studies per outcome. Mortality will be presented as a simple proportion with exact binomial confidence intervals, and pooled mortality estimates will be calculated using generalised linear mixed models (a normal-binomial model). For interventional studies, the outcomes in the usual care arm of the study only will be included in these estimates. Heterogeneity will be quantified with τ2, I2, and Cochran’s Q test. Exploratory meta-regression will be undertaken to explore heterogeneity by including covariates as fixed effects (e.g. year of recruitment, proportion of patients infected with HIV, median age) and testing for improved model fit by likelihood ratio testing of nested models. A p value of < 0.05 will be considered a statistically significantly improved fit. Summary estimates of one month mortality, where available, will be considered together and presented in the same way. Pooled prevalence estimates of malaria, acute bacterial or viral meningitis, encephalitis and bloodstream infection, will be calculated using random effects meta-analysis as above. For these aetiology analyses, we will include all studies, regardless of coma definition, and will include both usual care and intervention arms of RCTs. A sensitivity analysis will also be performed at the outcome level using the high-quality studies only (15). A table of study characteristics will be provided and the risk of bias for included studies will be described throughout the synthesis.

**DISCUSSION**

This systematic review will be published in accordance with PRISMA guidelines, and the review process will be recorded through use of the PRISMA flow diagram (20). This systematic review will provide a transparent review of the available evidence in order to provide a more accurate understanding of the causes of non-traumatic coma in African children. In this section, the authors aim to discuss the conclusiveness of the data in addition to strengths and limitations of the review. We hope that this review will serve to raise awareness of this common presentation in African settings. This review will highlight gaps in the literature and therefore areas in which future research is required.

**LIST OF ABBREVIATIONS**

CM: cerebral malaria

ABM: acute bacterial meningitis

MRI: magnetic resonance imaging

EEG: electroencephalogram

PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols

PICOS: Population, Intervention, Comparator, Outcome and Study Designs

PCR: polymerase chain reaction

HIV: human immunodeficiency virus

EPOC: Effective Practice and Organisation of Care

NOS: Newcastle-Ottawa Scale

CASP: Critical Appraisal Skills Programme

**DECLARATIONS**

**Ethics Approach and Consent to Participate**

Not applicable

**Consent for Publication**

Not applicable

**Availability of Data and Materials**

Not applicable

**Competing Interests**

The authors declare that they have no competing interests.

**Funding** Stephen Ray is funded by a Wellcome Trust Training Fellowship [grant number 203919/Z/16/Z]. Laura Bonnett is funded by a post-doctoral fellowship from the National Institute for Health Research [grant number PDF-2015-08-044]. No funder, sponsor, nor institution had any role in the development of this protocol.

**Authors’ Contributions**

SR, MG, and CF conceived and designed the systematic review. SR and CF developed the search strategy, and LB developed the statistical strategy for the review. CF and AB drafted the protocol manuscript, and SR, KBS, MG and LB contributed to the critical revision of the manuscript for methodological and intellectual content. SR is the guarantor of the review. All authors approved the final version of the submitted manuscript.

**Acknowledgements**

We acknowledge the support of Cochrane Effective Practice Organisation of Care.

**Amendments**

In the event of protocol amendments, a description of the change and rationale will be documented with the date of amendment.

**REFERENCES**

1. Mallewa M, Vallely P, Faragher B, Banda D, Klapper P, Mukaka M, et al. Viral CNS infections in children from a malaria-endemic area of Malawi: a prospective cohort study. The Lancet Global health. 2013;1(3):e153-60.

2. Ibekwe RC, Ibekwe MU, Onwe OE, Nnebe-Agumadu UH, Ibe BC. Non traumatic childhood coma in Ebonyi State University Teaching Hospital, Abakaliki, South Eastern Nigeria. Niger J Clin Pract. 2011;14:43–6.

3. Fouad H, Haron M, Halawa EF, Nada M. Nontraumatic coma in a tertiary pediatric emergency department in Egypt: etiology and outcome. J Child Neurol. 2011;26:136–41.

4. Lindblade KA, Steinhart L, Samuels A, Kachur SP, Slutsker L. The silent threat: asymptomatic parasitaemia and malaria transmission. Expert Rev Anti Infect Ther. 2013 Jun; 11(6):623-39

5. Newton CR. Viral infections of the CNS in sub-Saharan Africa: interaction with Plasmodium falciparum. The Lancet Global health. 2013;1(3):e121-2.

6. Gwer S, Thuo N, Idro R, Ndiritu M, Boga M, Newton C, et al. Changing trends in incidence and aetiology of childhood acute non-traumatic coma over a period of changing malaria transmission in rural coastal Kenya: a retrospective analysis. BMJ open. 2012;2(2):e000475.

7. Pelkonen T, Roine I, Monteiro L, Correia M, Pitkaranta A, Bernardino L, et al. Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in sub-Saharan Africa. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(8):1107-10.

8. Anga G, Barnabas R, Kaminiel O, Tefuarani N, Vince J, Ripa P, et al. The aetiology, clinical presentations and outcome of febrile encephalopathy in children in Papua New Guinea. Annals of tropical paediatrics. 2010;30(2):109-18.

9. Gwer S, Chacha C, Newton CR, Idro R. Childhood acute non-traumatic coma: aetiology and challenges in management in resource-poor countries of Africa and Asia. Paediatrics and International Child Health. 2013: 33(3): 129-138.

10. Brim R, Mboma S, Semrud-Clikeman M, Kampondeni S, Magen J, Taylor T, Langfitt J. Cognitive Outcomes and Psychiatric Symptoms of Retinopathy-Positive Cerebral Malaria: Cohort Description and Baseline Results. Am J Trop Med. 2017;97(1):225-231.

11. Boivin MJ, Mohanty A, Sikorskii A, Vokhiwa M, Magen JG, Gladstone M. Early and middle childhood developmental, cognitive, and psychiatric outcomes of Malawian children affected by retinopathy positive cerebral malaria. Child Neuropsychol. 2018;23:1-22.

12. Carter JA, Neville BG, Newton CR. Neuro-cognitive impairment following acquired central nervous system infections in childhood: a systematic review. Brain Res Brain Res Rev. 2003;43:57–69.

13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 2009;339:b2700

14. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, PRISMA-P Group. Preferred reporting items forsystematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015 Dec 02;350:g7647

15. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. 2011. URL <http://handbook-5-1.cochrane.org/>

16. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available: <http://www.cochrane-handbook.org/>. Accessed 20 March 2019.

17. Cochrane Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC Resources for review authors, 2017. Available at: <http://epoc.cochrane.org/epoc-specific-resources-review-authors>

18. Critical Appraisal Skills Programme (n.d.). Critical Appraisal Checklists. Available from

<https://casp-uk.net/casp-tools-checklists/>

19. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>

20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.

**APPENDIX**

**Table 1.** PRISMA-P Checklist

| **Section/Topic** | **#** | **Checklist Item** | **Information Reported** | | **Line Number(s)** |
| --- | --- | --- | --- | --- | --- |
| **Yes** | **No** |
| **ADMINISTRATIVE INFORMATION** | | | | | |
| **Title** | | | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | Yes |  |  |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | N/A | |  |
| **Registration** | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | Yes |  |  |
| **Authors** | | | | | |
| Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | Yes |  |  |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | Yes |  |  |
| **Amendments** | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | N/A | |  |
| **Support** | | | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | Yes |  |  |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | N/A | |  |
| Role of Sponsor/Funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | N/A | |  |
| **INTRODUCTION** | | | | | |
| **Rationale** | 6 | Describe the rationale for the review in the context of what is already known | Yes |  |  |
| **Objectives** | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | Yes |  |  |
| **METHODS** | | | | | |
| **Eligibility Criteria** | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | Yes |  |  |
| **Information Sources** | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | Yes |  |  |
| **Search Strategy** | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | Yes |  |  |
| ***STUDY RECORDS*** | | | | | |
| Data Management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | Yes |  |  |
| Selection Process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | Yes |  |  |
| Data Collection Process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | Yes |  |  |
| **Data Items** | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | Yes |  |  |
| **Outcomes and Prioritization** | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | Yes |  |  |
| **Risk of Bias in Individual Studies** | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | Yes |  |  |
| ***DATA*** | | | | | |
| **Synthesis** | 15a | Describe criteria under which study data will be quantitatively synthesized |  |  |  |
| 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., *I* 2, Kendall’s tau) |  |  |  |
| 15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) |  |  |  |
| 15d | If quantitative synthesis is not appropriate, describe the type of summary planned |  |  |  |
| **Meta-bias(es)** | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) |  |  |  |
| **Confidence in Cumulative Evidence** | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) |  |  |  |

**Table 2.** MEDLINE Search Strategy

| Number | Search terms |
| --- | --- |
| **1** | Coma\* OR consciousness OR unconscious OR “non-traumatic coma” OR “non traumatic coma” OR “nontraumatic coma” OR encephalopathy OR “febrile encephalopathy” NOT “head injury” |
| **2** | aetiology OR aetiologies OR etiology OR etiologies OR cause OR causes OR causality |
| **3** | Paediatric OR pediatric OR child\* |
| **4** | Africa OR “sub Saharan Africa” OR “sub-Saharan Africa” OR Algeria OR Angola OR Benin OR Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR “Cape Verde” OR “Central African Republic” OR Chad OR Comoros OR “Republic of the Congo” OR “Democratic Republic of the Congo” OR “Cote d’Ivoire" OR Djibouti OR Egypt OR “Equatorial Guinea” OR Eritrea OR Eswatini OR Ethiopia OR Gabon OR “The Gambia” OR Ghana OR Guinea OR “Guinea-Bissau" OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR “Sao Tome and Principe” OR Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR “South Africa” OR “South Sudan” OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe |
| **5** | #1 AND #2 AND #3 AND #4 |